Physician profile
Krystal Patrick
NPI 1558997247
$4,097.68
in general payments reported to CMS, 2019-2025
16 companies · $1,359 in 2025
The $1,359 reported for 2025 was more than what 86% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $111 · 2022: $477 · 2023: $622 · 2024: $1,528 · 2025: $1,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,509.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $864.05 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $792.28 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $581.49 | 2021-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $367.97 | 2023-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $315.79 | 2022-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $250.11 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $231.51 | 2024-2025 | Auvelity |
| Lundbeck LLC | $181.58 | 2023-2025 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $178.67 | 2022-2025 | Lybalvi, Aristada |
| E.R. Squibb & Sons, L.L.C. | $112.82 | 2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $90.72 | 2025 | Fanapt |
| Corium, LLC | $37.00 | 2024 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $31.16 | 2022-2023 | Austedo |
| Noven Therapeutics, LLC | $29.72 | 2024 | Xelstrym, Secuado |
| Neurocrine Biosciences, INC. | $16.46 | 2023 | Ingrezza |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $16.35 | 2024 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krystal Patrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.